| Revenue growth | 19.5% YoY for FY26. |
|---|---|
| Margins | EBITDA margin stable at ~36%; PAT margin at 18.6%. |
| Demand visibility | High in Pharma Analytical and Food Testing sectors. |
Growth
FY26 Revenue grew 19.5% YoY to ₹4,163 Mn; PAT increased 16.1% to ₹775 Mn. EBITDA margin stood at 35.8%.
Outlook
FY26 Capex was ₹998 Mn. Focusing on high-growth segments like Electronics and Drug Discovery to leverage global market opportunities.
Risks
Potential impact of new Labour Codes; global economic conditions and currency fluctuations affecting overseas revenue (36% in Pharma).
Earnings Call filed with NSE, NSE: VIMTALABS. Summary written with AI assistance from the document.
Vimta Labs Ltd: key numbers
- Share price
- ₹599.30
- Market cap
- ₹2,679 Cr
- Revenue (annual)
- ₹407.3 Cr
- Net profit (annual)
- ₹77.51 Cr
- P/E (TTM)
- 33.6×Sector 57.8×
- Promoter holding
- 35.67%-0.18% QoQ
- FII holding
- 4.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vimta Labs Ltd
All →Vimta Labs Employee Stock Options
Vimta Labs allotted 12,955 ESOP shares under its 2021 plan. Paid-up capital rose to ₹8,93,99,718, raising dilution for shareholders.
Vimta Labs Credit Rating
CARE Ratings has reaffirmed the bank facility ratings of Vimta Labs Limited. The disclosure updates stakeholders on the company's ongoing credit facilities.
Vimta Labs Investor Presentation: Key Takeaways
Vimta Labs reported Q1 FY27 total income of INR 1,129 million, up 13.7% YoY. Strategy focuses on diversifying into Biologics (CRAD) and strengthening domestic food testing.
- Call
- Guides 25% growth
Vimta Labs Earnings Call: Key Takeaways
Vimta Labs reports 13.7% YoY revenue growth in Q1 FY27, driven by strong performance in Pharma and Food testing segments with a 36.4% EBITDA margin.
Vimta Labs Q1 FY27 Results: Net Profit ₹21 Cr, Up 11.1% YoY
Vimta Labs Ltd reported revenue from operations of ₹109.1 Cr (+11.8% YoY) and net profit of ₹21 Cr (+11.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹21 Cr · +11.1% YoY
Vimta Labs Earnings Call: Key Takeaways
Vimta Labs reported Q4 FY26 revenue of ₹1,120M (+16.6% YoY) and FY26 revenue of ₹4,163M (+19.5% YoY). Strategy focuses on core pharma/food testing and entry into biologics.